Patents by Inventor Julie G. Beitz

Julie G. Beitz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment of tumorigenic pathophysiological conditions with FGF-cytoxic conjugates
    Patent number: 5478804
    Abstract: Conjugates comprising bFGF or other FGF polypeptides and a cytotoxic agent are prepared. The cytotoxic agent can be a ribosome-inactivating protein (RIP), such as saporin, which is attached to bFGF through a chemical bond, or the composition can be prepared as a recombinant DNA chimera. The conjugates are used to specifically target cells, in vivo and in vitro, which express FGF receptors. The cytotoxicity of the conjugates is proportional to the number of receptors expressed by a cell type. The conjugate is useful to effectively treat mammals, and in particular human patients, afflicted with tumorigenic conditions, such as human melanomas, human ovarian carcinomas, teratocarcinomas and neuroblastomas, and other FGF-mediated tumors caused by a proliferation of cells which express FGF receptors.
    Type: Grant
    Filed: May 26, 1994
    Date of Patent: December 26, 1995
    Assignees: The Salk Institute for Biological Studies, Roger Williams General Hospital
    Inventors: Paul Calabresi, Julie G. Beitz, Jeffrey W. Clark, A. Raymond Frackelton, Jr., Douglas A. Lappi, Andrew J. Baird